Serrapeptase

Serrapeptase is a proteolytic enzyme produced by Serratia bacteria found in the digestive tract of the silkworm, where it is thought to help the emerging moth dissolve its cocoon. Commercial material is produced by bacterial fermentation rather than harvested from insects.

Potency is expressed in enzyme activity units, usually SPU or SU, rather than milligrams. Common servings are 40,000 to 120,000 SPU. As with other enzyme supplements, a milligram figure alone conveys little about potency.

Enteric coating is essential rather than optional. Stomach acid destroys the enzyme, so an uncoated product delivers substantially reduced activity to the small intestine where absorption occurs. This is a meaningful quality differentiator between products.

Serrapeptase breaks peptide bonds in proteins. The proposed rationale is that it preferentially degrades non-living protein material such as fibrin, cellular debris and the fluid that accumulates in swollen tissue, while leaving healthy tissue intact.

By breaking down fibrin, it is proposed to reduce swelling and improve drainage from affected tissue. Effects on the mediators involved in swelling have also been described.

There has been separate research interest in its ability to disrupt biofilms, the protein matrices that bacteria build to shelter themselves. This is mostly laboratory work but is one of the more interesting strands.

Serrapeptase has been used clinically in Japan and parts of Europe for decades, principally for post-operative and post-traumatic swelling, and there is a body of older clinical research supporting those applications.

That literature is dated by modern standards, often small, and much of it predates current methodological expectations. Some jurisdictions have withdrawn approval for the pharmaceutical product on efficacy grounds, which is a meaningful counterweight to the enthusiasm found in supplement marketing.

Modern high-quality trials are scarce, and there is very little evidence for the broader claims made in the supplement space regarding arterial plaque, scar tissue or chronic inflammatory conditions. The gap between what the older clinical literature examined and what the supplement market claims is substantial.

Generally reported as well tolerated, with mild digestive upset, nausea and occasional skin reactions being the most common complaints. Decades of use provide some reassurance.

There are documented reports of respiratory and skin reactions associated with serrapeptase. These are uncommon but not negligible, and anyone who develops breathing difficulty or a rash should stop and seek advice.

Because it breaks down the protein scaffold of clots, there is potential to increase bleeding risk, particularly alongside medication that thins the blood. It should be stopped in advance of surgery.